Unknown PHASE3 INTERVENTIONAL 2-arm NCT05613127

To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24mons-15yrs

A Randomized, Double-blind, Multicenter, Multinational, Active-controlled, Parallel-designed Phase 3 Clinical Trial to Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24months to 15yrs

Sponsor: Boryung Biopharma Co., Ltd.

Conditions Hep A Hepatitis A

Interventions Boryung Hepatitis A Vaccine Pre-Filled Syringe Inj. 0.5 mL HAVRIX 720 Junior 0.5 mL

Updated 5 times since 2022 Last updated: Nov 4, 2022 Started: Dec 31, 2022 Primary completion: Jul 31, 2024 Completion: Nov 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Hep A and Hepatitis A, this trial is ongoing. The trial is conducted by Boryung Biopharma Co., Ltd. and has accumulated 5 data snapshots since 2022. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE3
Dec 2024 — Sep 2025 [monthly]

Unknown PHASE3

Status: Not Yet Recruiting → Unknown
Sep 2024 — Dec 2024 [monthly]

Not Yet Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE3
Dec 2022 — Jul 2024 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boryung Biopharma Co., Ltd.

Data source: Boryung Biopharma Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chiang Mai, Thailand
• Suwon, South Korea